News 12 February 2024 Launch of ANDROMEDA 2.0 ANDROMEDA 2.0 will be launched on Feb 15th. Welcome to attend our release event in… Urban Fagerholm
News 10 July 2023 PROSILICO is happy to announce a strategic partnership with Phenaros Pharmaceuticals PROSILICO is happy to announce a strategic partnership with Phenaros Pharmaceuticals (https://www.phenaros.com/). Together, we will… Urban Fagerholm
News 13 June 2023 PROSILICO will attend and present at 2 conferences PROSILICO will attend and present at Biotech Hanse in Stockholm and RSC Anglo-Nordic Medicinal Chemistry… Urban Fagerholm
News 22 May 2023 PROSILICO attended IDDST in Tokyo and presented new results PROSILICO attended IDDST in Tokyo 8-10 May and gave an oral presentation of new ANDROMEDA… Urban Fagerholm
Scientific publications 22 May 2023 In silico predictions of the hepatic metabolic clearance in humans for 10 drugs with highly variable in vitro pharmacokinetics Fagerholm U. In silico predictions of the hepatic metabolic clearance in humans for 10 drugs… Urban Fagerholm
Scientific publications 22 May 2023 Application of the ANDROMEDA software for prediction of the human pharmacokinetics of modern anticancer drugs Fagerholm U, Hellberg S, Alvarsson J, Spjuth O. bioRxiv, March 2023.https://www.biorxiv.org/content/10.1101/2023.03.18.533259v1 Urban Fagerholm
Scientific publications 22 May 2023 Prediction of the human pharmacokinetics of 30 modern antibiotics using the ANDROMEDA software Fagerholm U, Hellberg S, Alvarsson J, Spjuth O. bioRxiv, March 2023.https://www.biorxiv.org/content/10.1101/2023.03.28.534601v1 Urban Fagerholm
News 21 March 2023 ANDROMEDA by Prosilico outperforms laboratory methods In 49 study comparisons, ANDROMEDA by Prosilico outperformed laboratory methods in 74 % of cases… Urban Fagerholm
News 21 March 2023 PROSILICO participates in the planned SciLifeLab PULSE cofund postdoctoral programme PROSILICO participates in the planned SciLifeLab PULSE cofund postdoctoral programme SciLifeLab has the ambition to… Urban Fagerholm